Published in Cancer Weekly, March 30th, 2004
Under the terms of the agreements, the companies will work together to develop molecular imaging agents for cardiovascular diseases and cancer using Kereos' core technology. Bristol-Myers Squibb Medical Imaging has obtained exclusive worldwide rights to develop and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.